Latest posts tagged with #her2 on Bluesky
Synapse: Your Connection to our MSK Authors
Meet: Elisa De Stanchina
Research Focus: Res Facilities; Lab Member
Trastuzumab deruxtecan resistance via loss of HER2 expression and binding
synapse.mskcc.org/synapse/work...
#TrastuzumabDeruxtecan #HER2
#BreastCancerResearch #TargetedTherapy #Oncology
Call for Papers: This Special Collection examines clinical and translational developments in high‑risk HER2+ early breast cancer, including response‑adapted strategies, ADCs, and biomarker‑guided approaches. buff.ly/3jv7zmw #BreastCancer #Oncology #HER2 #MedOnc #ClinicalTrials
Nuestro póster destaca cuatro clases terapéuticas clave en oncología:
🔬 #ADC (conjugados anticuerpo-fármaco)
🎯 Terapias dirigidas a #HER2
🧬 Inhibidores de #CDK4/6
💊 Inhibidores de #PARP
#CancerDeMama #Oncología #InnovacionFarmaceutica #Farmaceutica #SaludGlobal #DengYueMedicinasEnHongKong
Dr Dennis Slamon's journey as the pioneer of Herceptin, inspires a movie of his life, "Living Proof."
Dr. Dennis Slamon's Inspiration Behind "Living Proof" | Stand Up To Cancer
youtube.com/watch?v=vsa7...
YouTube, Stand Up To Cancer
#Herceptin #HER2
📊 En este póster compartimos 5 empresas biofarmacéuticas chinas líderes en innovación contra el cáncer de mama y algunas de sus terapias clave.
💬 ¿Conocías alguna de estas compañías?
#CáncerDeMama #ADC #HER2 #InhibidoresCDK46 #InnovaciónEnSalud #DengYueMedicinasEnHongKong
China impulsa la innovación en oncología.
📊 Descubre en este póster 5 medicamentos innovadores para el cáncer de mama.
#CáncerDeMama #Dalpiciclib #Pyrotinib #Chidamide #Envafolimab #DisitamabVedotin #HER2 #HER2Positive #TargetedTherapy #ADC #TerapiasInnovadoras #DengYueMedicinasEnHongKong
Ther Adv Med Oncol: Real‑world pyrotinib beyond progression vs rechallenge in HER2+ mBC (incl. brain mets): PFS2 ~7.2 vs 6.3 mo (NS); OS 31.6 vs 21.0 mo (trend). CNS subgroup also benefited. Read: 【🔗https://buff.ly/xsK4lFw 】 #BreastCancer #HER2 #BrainMets #Oncology
💊FDA Approval Update | #HERNEXEOS® (#zongertinib tablets): the first targeted therapy for #HER2 mutant advanced #NSCLC
🔹For adults as an initial treatment option
🔹11% of patients with a complete response
🔹65% of patients with a partial response
Zongertinib Receives FDA Accelerated Approval in HER2-Mutant NSCLC
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #NSCLC #MedEd #MedOnc #MedNews #LungCancer #HER2 #TargetedTherapy #FDAApproval
Analysis of 346 BCBM cases from the GEICAM RegistEM registry reveals faster CNS progression and poorer survival in TNBC and HER2+ subtypes, with major differences between de novo vs subsequent brain metastases.
🔗 buff.ly/74yHwuH
#BreastCancer #BrainMets #HER2 #TNBC #RealWorldEvidence
Register:
give.cancergrace.org/event/lung-c...
Support free patient education 💙 #LungCancer #EGFR #HER2
Neutrophil-to-lymphocyte ratio (NLR) shows moderate value in predicting #BreastCancer grade and #HER2 status — a simple, low-cost blood marker with potential for early risk stratification.
#Oncology #Biomarkers #NLR link.springer.com/article/10.1...
Synapse: Your Connection to our MSK Authors
Meet: Sohrab Prakash Shah
Research Focus: BIOSTAT/EPIDEMIOLOGY; Chief Attending
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer
synapse.mskcc.org/synapse/work...
#UrothelialCancer #BladderCancer #HER2
Antibody Therapeutics(IF=4.5, Oxford University Press)
📢📢Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity
academic.oup.com/abt/article/...
#ADC #HER2 #Antibody
ctDNA findings from the Ni‑High phase Ib trial: ERBB2 focal amplification and early mMAF decline strongly predict improved outcomes with trastuzumab + nivolumab + chemo in HER2+ aGC.
🔗https://buff.ly/S2kBuFe
#GastricCancer #HER2 #ctDNA
第一三共、エンハーツが中国でHER2陽性胃がん二次治療に承認──DESTINY-Gastric04に基づく
ENHERTU (trastuzumab deruxtecan) approved in China for second-line HER2-positive gastric cancer based on DESTINY-Gastric04
stellanews.life/technology/8...
#GastricCancer #HER2 #ENHERTU #AntibodyDrugConjugate #DESTINYGastric04
【第一三共、HER2陽性胃がん二次治療で中国承認】
✔ トラスツズマブ前治療後のHER2陽性進行・再発胃がんで承認
✔ 第3相DESTINY-Gastric04に基づく判断
✔ 画期的治療薬指定・優先審査の下で取得
トラスツズマブ デルクステカン（商品名エンハーツ）は抗HER2抗体薬物複合体。中国では三次治療で条件付き承認済みで、今回は二次治療に拡大。生存期間など詳細指標は本発表では限定的であり、追加データの確認が必要。
#胃がん #HER2 #抗体薬物複合体
When first-line cancer treatment stops working, knowing your options and speaking up matters. This man shares his experience with second-line HER2 therapy, biopsy decisions, and why self-advocacy can shape your care journey. #CancerCare #SelfAdvocacy #HER2 #PatientEmpowerment #Oncology
#Article in @MedComm_MC
Triple #HER2 Blockade With #Trastuzumab, #Pertuzumab, and #Pyrotinib Versus Dual HER2 Blockade in the #Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Randomized, Phase II Study doi.org/10.1002/mco2...
#ClinicalTrial
Zanidatamab (Baihe’an®): Un avance clave en el cáncer de vías biliares HER2 positivo
📩 info@dengyuemed.com
🔗https://dengyuepharma.com
#Zanidatamab #BaiheAn #HER2 #BiliaryTractCancer #Oncology #BispecificAntibody #TargetedTherapy #BreakthroughTherapy #CSCO #CDE #FDA
#brca #hereditarycancer #genetics #patientexperience
#EarlyDetection #her2 #prostatecancer #breastcancer #cysticfibrosis #sicklecell #heartdisease #diabetes #pancreaticcancer
fed.brid.gy/bsky/globalv...
#HER2 #NEU
headlines-world.com/advanced-sea...
ПЛАЖА ЈУТА
multi-search-tag-explorer.headlines-world.com/advanced-sea...
#MIROSLAV #BENKA
multi-search-tag-explorer.headlines-world.com/advanced-sea...
aepiot.com
La #FDA a accordé la désignation de "thérapie révolutionnaire" au #Sévabertinib pour le traitement de 1ère intention des patients atteints de #CancerDuPoumon non à petites cellules non réséquable ou métastatique présentant des mutations activatrices #HER2
www.targetedonc.com/view/fda-gra...
Join Rachna Shroff, MD, MS, FASCO at an ASCO GI 2026 satellite symposium exploring HER2-positive GI cancers, from molecular testing to targeted therapy across gastric/GEJ, CRC, and biliary tract cancers.
👉 Register: https://bit.ly/48FksQl
#ASCOGI2026 #HER2 #GICancers
The role of HER2 in advanced bladder cancer is rapidly expanding.
📖 Read the full clinical thought commentary for expert perspectives on testing strategies, treatment sequencing, and future directions in HER2-positive urothelial carcinoma: https://bit.ly/4pIHX11
#HER2 #BladderCancer
Lunit SCOPE Achieves Remarkable Concordance with Pathologists in HER2 Analysis for Advanced Biliary Tract Cancer #South_Korea #Seoul #Lunit #HER2 #Biliary_Cancer
🎙️ New episode: HER2 Uncovered – From Low to Ultralow
A/Prof Ben Dessauvagie & Prof Gelareh Farshid explore HER2 ultralow breast cancer, evolving pathology practice and implications for MDT decision-making.
🎧 Listen now: t.ly/3E4kJ | #BeyondtheSlide #HER2 #HER2Ultralow #Oncology#MedEd #BreastCancer
Join Matthew Gubens, MD, MS, FASCO and Estelamari Rodriguez, MD, MPH this Tuesday for a 1-hour expert discussion on the latest insights in HER2-altered NSCLC.
A concise, practical session designed to support real-world decision-making 👉 https://bit.ly/451c6QE
#MedicalEducation #CME #NSCLC #HER2
💊FDA Approval Update | #Hyrnuo (#sevabertinib)
🔸For #HER2-mutant non-small cell lung cancer #NSCLC
⚙️Reversible tyrosine kinase inhibitor targets #EGFR and #HER2 protein
🌟MedChemExpress provides #Sevabertinib for research use.
#NSCLC #TyrosineKinaseInhibitor #TKI #FDA #FDAApproval
The #FDA has given accelerated approval to #Bayer for oral #HER2 tyrosine kinase inhibitor sevabertinib as a second-line treatment for advanced HER2-mutant #NSCLC, allowing it to challenge #BoehringerIngelheim's recently approved Hernexeos.
pharmaphorum.com/news/bayer-t...
